Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction
Date:8/20/2008

CHENGDU, China, Aug. 20 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc. (OTC Bulletin Board: TYNP, TYNPE), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that the Company's stock symbol had been inadvertently changed to OTC BB: TYNPE due to the electronic eligibility system error.

The error is being corrected immediately and the Company expects the stock symbol to trade under the symbol OTC BB: TYNP on Thursday, August 21, 2008.

Tianyin Pharmaceutical Co., Inc. is a fully-reporting company and the Company's fiscal year ends on June 30. The Company will file its 10K for FY2008 on a timely manner, which is due on September 30. The Company has been compliant is all its fillings.

"This symbol error was very unfortunate and we do wish to assure our shareholders that there is absolutely no problem with Tianyin Pharmaceutical," said Dr. Jiang, Chairman and CEO of Tianyin Pharmaceutical Co., Inc. ''We will announce earnings results for fiscal year 2008 that ended June 30, 2008 before the reporting deadline of September 30, 2008. Additionally, we would like to reiterate that the Company expects to exceed its fiscal year 2008 make good of $5.6 million in net income or fully diluted EPS of $0.16 per share.''

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 34 modernized TCMs in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 51 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 523 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,187 employees. Tianyin achieved revenue of $20.4 million and net income of $3.95 million in FY2007 ending June 30, 2007. For more information about Tianyin Pharmaceuticals, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

Contacts:

For the Company:

Allen Tang, Ph.D., MBA, Assistant to the CEO

Tel: +86-158-2122-5642 (China)

Email: Allen.y.tang@gmail.com

Investors:

HC International, Inc.

Alan Sheinwald

Tel: 914-669-0222 (US)

Email: Alan.Sheinwald@hcinternational.net


'/>"/>
SOURCE Tianyin Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
2. Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tour in Beijing on May 20, 2008 at 12:40 p.m. Beijing Time
3. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
4. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
5. Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors
6. Tianyin Pharmaceutical Co., Inc. Completes Production for Earthquake
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
8. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... ... to announce the ATA 2017 President’s Awards recipients, comprised of organizations and ... healthcare delivery. , The ATA 2017 President’s Awards recognize individuals and ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility ... in pelvic conditions and has helped many women become pregnant upon treating their ... of office-based and simple outpatient evaluations. We can provide the necessary information ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... an agile ecosystem and domain expertise for sponsors and CROs to speed ... trial supply management (RTSM) software platform. Bioclinica AGILE RTSM provides ...
(Date:4/25/2017)... , ... April 25, 2017 ... ... in Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, ... from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in ...
(Date:4/25/2017)... ... 2017 , ... Lake Park Dental is now accepting new patients with crooked ... FL. With the help of this highly-effective, yet convenient system, patients can straighten their ... and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group ... it is developing at Conejo Spectrum Business Park ... to Atara Biotherapeutics, Inc. , a biopharmaceutical ... and life-threatening diseases that have been underserved by ... T-cell therapies for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... , April 18, 2017 Viverae ® , ... announce the integration of IBM ® Watson Campaign ... deliver targeted communications for a personalized experience. Through digital ... on their health in real time. The enhanced experience ... most to members, wherever they are in their journey ...
(Date:4/18/2017)... and BLOOMINGTON, Minn. ... (NASDAQ: IMMY ) ("Imprimis"), an ophthalmology-focused ... Lens ("Precision Lens"), today announced the signing of ... agreement, Precision Lens will deploy a dedicated sales ... geographies in the U.S., primarily focused in 13 ...
Breaking Medicine Technology: